A decades-long quest to outmaneuver HIV’s legendary evasiveness has reached a critical milestone. Researchers at the La Jolla Institute for Immunology (LJI) and Scripps Research, working within the Scripps Consortium for HIV/AIDS Vaccine Development, have engineered a vaccine that reliably coaxes the primate immune system to produce potent, broadly neutralizing antibodies against the virus. In a study published in Nature, the team reports that their multi-step immunization regimen drove rhesus macaques to generate high titers of antibodies capable of recognizing and neutralizing a wide swath of HIV variants—marking the most robust such response ever achieved in an animal model by vaccination.
The central challenge confronting HIV vaccine developers is the virus’s formidable defensive toolkit. HIV cloaks its outer envelope protein in a dense shield of host-derived sugar molecules, or glycans, effectively camouflaging itself from immune surveillance. At the same time, the virus mutates with extraordinary speed, generating immense global diversity and even dramatic sequence variation within a single infected individual. To compound the problem, the envelope protein undergoes rapid conformational shape-shifting during cell entry, presenting a constantly moving target. These three hurdles mean that, in most people, the B-cell bootcamp that normally refines antibodies into precision weapons never gets the time and stable targets it needs to succeed. A protective vaccine must somehow teach the immune system to see past the disguise, ignore the mutational noise, and home in on conserved, vulnerable structures.
The new vaccine achieves this by targeting the earliest, naïve precursors of antibody-producing B cells—an approach termed germline targeting. The team spent years studying the rare individuals living with HIV who do eventually develop so-called broadly neutralizing antibodies (bnAbs), reverse-engineering the precise evolutionary path their B cells took. They identified that these special B cells needed to encounter specific pieces of the virus’s envelope antigen very early in their development. Acting on that insight, the Schief lab at Scripps designed a series of synthetic immunogens that mimic the critical antigenic structures HIV uses to infect cells, but are optimized to selectively activate and guide naïve B cells along the correct developmental trajectory.
The immunization strategy unfolded in two phases. First, a “priming” immunogen was administered to wake up the desired germline B-cell precursors and set them on the path toward bnAb production. This was followed by a sequence of “shepherding” booster shots, each tailored to further refine the maturing B cells, pushing them to accrue the key mutations that confer neutralization breadth. Conceptually, the vaccine walks a B cell from its naïve state to a fully mature, broadly neutralizing state through an orchestrated series of antigenic encounters.
The results in rhesus macaques, a standard non-human primate model for HIV research, were striking. Approximately 44 percent of vaccinated animals went on to produce broadly neutralizing antibodies in their blood. These antibodies were not only present but were remarkably abundant—successfully transforming what is typically an ultra-rare immune response into a common one by the end of the vaccination process. While the study did not directly test whether these antibodies prevent infection, their presence at meaningful levels in the bloodstream, precisely where they could intercept an incoming virus, represents a crucial proof of principle.
The antibodies elicited in the macaques closely resembled the broadly neutralizing antibodies isolated from those rare human individuals who naturally produce them, confirming that the developmental pathway the vaccine instructs is biologically authentic. According to the researchers, the achievement validates more than a decade of methodical, iterative molecular engineering. Shane Crotty, LJI’s Chief Scientific Officer and co-leader of the study, compared the effort to an Apollo moon mission: a singular goal that demanded a cascade of fundamental discoveries and inventions along the way.
The priming immunogen used in this primate study has already been tested in humans through the HVTN 144 trial and is currently undergoing further evaluation in the Phase 1 clinical study IAVI G004, being run by IAVI, Scripps Research, and the HIV Vaccine Trials Network. Plans are now advancing to test the complete immunization regimen—the prime and the shepherding boosts—in a future human clinical trial. Crotty noted that the vaccine approach is even more likely to succeed in humans, given favorable immunogenetic factors that could further enhance the response.
The team is now working to push the responder rate beyond 44 percent, investigating refinements to the booster schedule and regimen composition. They are also exploring complementary strategies, recently reported in Nature Immunology, to accelerate the maturation of similar protective antibody responses. For the first time, the field has a vaccine platform that can reliably shepherd the immune system through the intricate process of building potent, broadly neutralizing defenses against HIV. It is no longer a question of whether bnAbs can be induced by vaccination, but of how quickly this platform can be optimized and translated into a globally deployable shield against one of humanity’s most persistent viral foes.
Subject of Research: Animals (rhesus macaques)
Article Title: Vaccination elicits HIV broadly neutralizing antibodies in primates
News Publication Date: 30-Jun-2026
Web References: https://www.nature.com/articles/s41586-026-10837-5
References: Nature, DOI: 10.1038/s41586-026-10837-5
Image Credits:
Keywords: HIV vaccine, broadly neutralizing antibodies, germline targeting, B cell maturation, envelope glycans, Scripps Research, La Jolla Institute for Immunology, rhesus macaques, IAVI G004, HIV Vaccine Trials Network, shepherding immunogens, viral evasion
